2/2
03:24 am
tak
Is Takeda's Upgraded FY2025 Outlook And New PID Therapy Altering The Investment Case For Takeda (TSE:4502)? [Yahoo! Finance]
Low
Report
Is Takeda's Upgraded FY2025 Outlook And New PID Therapy Altering The Investment Case For Takeda (TSE:4502)? [Yahoo! Finance]
2/2
12:26 am
tak
Takeda Pharmaceutical (TSE:4502) Valuation Check After Recent Share Price Momentum And Mixed Fair Value Signals [Yahoo! Finance]
Low
Report
Takeda Pharmaceutical (TSE:4502) Valuation Check After Recent Share Price Momentum And Mixed Fair Value Signals [Yahoo! Finance]
1/31
09:57 am
tak
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? [Yahoo! Finance]
Low
Report
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? [Yahoo! Finance]
1/31
01:33 am
tak
Takeda Pharmaceutical (NYSE:TAK) was upgraded by analysts at
Wall Street
Low
Report
Takeda Pharmaceutical (NYSE:TAK) was upgraded by analysts at
Wall Street
1/30
02:16 pm
tak
Takeda Tests New Highs, But Struggles To Find Entyvio Successor [Seeking Alpha]
Low
Report
Takeda Tests New Highs, But Struggles To Find Entyvio Successor [Seeking Alpha]
1/29
01:37 am
tak
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
Medium
Report
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
1/22
07:45 am
tak
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹
Low
Report
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹
1/21
07:04 pm
tak
Assessing Takeda Pharmaceutical (TSE:4502) After Recent Pipeline Progress And Share Price Moves [Yahoo! Finance]
Low
Report
Assessing Takeda Pharmaceutical (TSE:4502) After Recent Pipeline Progress And Share Price Moves [Yahoo! Finance]
1/13
08:42 am
tak
Takeda Pharmaceutical (NYSE:TAK) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Low
Report
Takeda Pharmaceutical (NYSE:TAK) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
1/9
05:18 pm
tak
Takeda Pharmaceutical (TSE:4502) Valuation Check As Shares Show Strength Over Recent Periods [Yahoo! Finance]
Low
Report
Takeda Pharmaceutical (TSE:4502) Valuation Check As Shares Show Strength Over Recent Periods [Yahoo! Finance]
1/5
07:00 am
tak
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
Low
Report
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
12/30
11:04 am
tak
Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies [Yahoo! Finance]
Low
Report
Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies [Yahoo! Finance]
12/29
09:47 am
tak
Blending Data and Local Knowledge To Enable Sustainable Outcomes [Yahoo! Finance]
Low
Report
Blending Data and Local Knowledge To Enable Sustainable Outcomes [Yahoo! Finance]
12/24
09:31 pm
tak
????????????????????:???????????????????????????????????????????????????2033????61?3000????????????? [CNET News]
Low
Report
????????????????????:???????????????????????????????????????????????????2033????61?3000????????????? [CNET News]
12/18
04:24 am
tak
Takeda Pharmaceutical's Potential Plaque Psoriasis Therapy Meets Endpoints in Phase 3 Studies [Yahoo! Finance]
Low
Report
Takeda Pharmaceutical's Potential Plaque Psoriasis Therapy Meets Endpoints in Phase 3 Studies [Yahoo! Finance]
12/18
03:00 am
tak
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
Medium
Report
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
12/6
09:30 am
tak
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
Low
Report
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
11/28
07:12 am
tak
American Neurology Summit 2025 Achieves Major Success With Full Attendance and High Engagement
Low
Report
American Neurology Summit 2025 Achieves Major Success With Full Attendance and High Engagement
11/25
01:57 pm
tak
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
01:21 pm
tak
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
11/12
01:30 pm
tak
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Takeda Pharmaceutical (NYSE:TAK) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.